Proqr Therapeutics (PRQR) Stock Price, Quote & News

Company Profile

ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett...

Industry: Biotechnology

Sector: Healthcare

Phone: 31 88 166 7000

Website: www.proqr.com

Address:

Zernikedreef 9, Leiden, Netherlands

Chumpchange53 Jun. 2 at 5:44 PM

$PRQR Investing.com - Citizens reiterated a Market Outperform rating and $8.00 price target on ProQR Therapeutics N.V. (NASDAQ:PRQR) shares. The firm noted the high unmet need in biliary atresia, a condition affecting approximately 180-360 U.S. patients per year. . trial for approval, and Phase 3 data for odevixibat in the second half of 2026 could mark the first success for the field. If odevixibat fails, ProQR will have the only candidate in development for biliary atresia. The firm said it is interested in early data from ProQR’s Chinese investigator-initiated trial in the first half of 2027, as well as details on a potential development plan. The firm expects the first target engagement data for AX-0810 this quarter, which it views as a key catalyst that could move ProQR shares to approximately $5 in the near term. According to InvestingPro analysis, the stock appears undervalued at current levels.

0 · Reply

anlkrts Jun. 2 at 3:39 PM

$PRQR Shareholders meeting today.

1 · Reply

Syndr78 Jun. 2 at 8:27 AM

$PRQR people have mentioned data to be released sometime before the end of June. All I'm seeing is a possible corporate update for this month, and that ax-0810 data won't be until 2H 2026. What's the expectation for June, then??

1 · Reply

justfacts1 Jun. 2 at 4:32 AM

$PRQR Based on its original September 2021 agreement and the expanded agreement announced today with Lilly, in total, ProQR is eligible to receive up to approximately $3.75 billion in research, development and commercialization milestones. How much they receive so far?

1 · Reply

Shane_Drinion Jun. 1 at 6:38 PM

$PRQR JFC, just publish the unimpressive data so we can take our loss and move on with our lives.

1 · Reply

justfacts1 Jun. 1 at 5:21 PM

$PRQR Daniel de Boer, stated that key milestones from their Axiomer pipeline program, specifically the lead RNA editing program AX-0810, are expected to drive significant value for stakeholders? !!!

1 · Reply

ehpats Jun. 1 at 4:52 PM

$PRQR headed toward the one year lows of $1.37

0 · Reply

dirkfrank Jun. 1 at 2:34 PM

$PRQR

1 · Reply

biochirp May. 29 at 5:37 PM

$PRQR still lagging $XBI let’s see a move to 2$

1 · Reply

Filvul May. 29 at 2:08 PM

$PRQR what are the chances of "good news"?

1 · Reply

Market Cap	166.47M
Revenue (ttm)	18.00M
Net Income (ttm)	-47.73M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-265.17%
Debt to Equity Ratio	0.13

Volume	681,246
Avg Vol	648,004
Day's Range	N/A - N/A
Shares Out	105.36M
Stochastic %K	75%
Beta	0.08
Analysts	Strong Sell
Price Target	$8.88